UA72615C2 - Imidazopyrimidine and triazolopyrimidine derivatives, a method for the preparation thereof, medicament based thereon - Google Patents

Imidazopyrimidine and triazolopyrimidine derivatives, a method for the preparation thereof, medicament based thereon Download PDF

Info

Publication number
UA72615C2
UA72615C2 UA2002119418A UA2002119418A UA72615C2 UA 72615 C2 UA72615 C2 UA 72615C2 UA 2002119418 A UA2002119418 A UA 2002119418A UA 2002119418 A UA2002119418 A UA 2002119418A UA 72615 C2 UA72615 C2 UA 72615C2
Authority
UA
Ukraine
Prior art keywords
alkyl
substituent
group
optionally containing
optionally
Prior art date
Application number
UA2002119418A
Other languages
English (en)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UA72615C2 publication Critical patent/UA72615C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
UA2002119418A 2000-04-28 2001-04-17 Imidazopyrimidine and triazolopyrimidine derivatives, a method for the preparation thereof, medicament based thereon UA72615C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000128870A JP2001302667A (ja) 2000-04-28 2000-04-28 イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
PCT/EP2001/004357 WO2001083485A1 (en) 2000-04-28 2001-04-17 Imidazopyrimidine derivatives and triazolopyrimidine derivatives

Publications (1)

Publication Number Publication Date
UA72615C2 true UA72615C2 (en) 2005-03-15

Family

ID=18638240

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2002119418A UA72615C2 (en) 2000-04-28 2001-04-17 Imidazopyrimidine and triazolopyrimidine derivatives, a method for the preparation thereof, medicament based thereon

Country Status (38)

Country Link
US (1) US6911443B2 (ru)
EP (1) EP1278750B1 (ru)
JP (2) JP2001302667A (ru)
KR (1) KR20030009456A (ru)
CN (1) CN1263756C (ru)
AR (1) AR033367A1 (ru)
AT (1) ATE272639T1 (ru)
AU (1) AU783043B2 (ru)
BG (1) BG107166A (ru)
BR (1) BR0110404A (ru)
CA (1) CA2407531A1 (ru)
CZ (1) CZ20023551A3 (ru)
DE (1) DE60104671T2 (ru)
DK (1) DK1278750T3 (ru)
DO (1) DOP2001000151A (ru)
EE (1) EE200200606A (ru)
ES (1) ES2225546T3 (ru)
HK (1) HK1058362A1 (ru)
HR (1) HRP20020943A2 (ru)
HU (1) HUP0300846A2 (ru)
IL (1) IL151919A0 (ru)
MA (1) MA25746A1 (ru)
MX (1) MXPA02010579A (ru)
MY (1) MY141578A (ru)
NO (1) NO20025154L (ru)
NZ (2) NZ526221A (ru)
PE (1) PE20011287A1 (ru)
PL (1) PL358106A1 (ru)
PT (1) PT1278750E (ru)
RU (1) RU2306313C2 (ru)
SI (1) SI1278750T1 (ru)
SK (1) SK15332002A3 (ru)
SV (1) SV2001000416A (ru)
TR (1) TR200402300T4 (ru)
TW (1) TWI222974B (ru)
UA (1) UA72615C2 (ru)
WO (1) WO2001083485A1 (ru)
ZA (1) ZA200207676B (ru)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1385823E (pt) 2001-04-09 2007-01-31 Novartis Vaccines & Diagnostic Compostos de guanidino como agonistas do receptor de melanocortina-4 (r-mc4)
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
JPWO2005037837A1 (ja) * 2003-10-17 2006-12-28 日本化薬株式会社 置換2−アミノ−[1,2,4]トリアゾロ[1,5−a]ピリミジン誘導体及びその用途
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
BRPI0507123A (pt) 2004-01-31 2007-06-19 Actimis Pharmaceuticals Inc composto, medicamento, uso de um composto, e, processo para controlar um distúrbio ou doença associadas com a atividade de crth2 no ser humano e animais
WO2006004702A1 (en) * 2004-06-25 2006-01-12 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
JP2008510734A (ja) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
CN101039936A (zh) 2004-08-23 2007-09-19 惠氏公司 作为i-型纤溶酶原激活剂抑制剂(pai-1)调节剂用于治疗血栓形成和心血管疾病的唑基-萘基酸
ATE479687T1 (de) * 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
CA2599544A1 (en) 2005-02-28 2006-09-08 Japan Tobacco Inc. Novel aminopyridine compound with syk inhibitory activity
US7442700B2 (en) 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
PE20070593A1 (es) * 2005-10-13 2007-07-23 Glaxo Group Ltd Compuestos pirrolopirimidina como inhibidores de syk
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
SI2099447T1 (sl) * 2006-11-22 2013-03-29 Incyte Corporation Experimental Station E336/205 Imidazotriazini in imidazopirimidini kot inhibitorji kinaz
CA2673965A1 (en) 2006-12-28 2008-07-10 Taisho Pharmaceutical Co., Ltd. Pyrazolopyrimidine compound
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CA2700525A1 (en) 2007-09-25 2009-04-02 Actimis Pharmaceuticals, Inc. 2-s-benzyl substituted pyrimidines as crth2 antagonists
KR20100061747A (ko) 2007-09-25 2010-06-08 액티미스 파마수티컬스 인코포레이티드 Crth2 길항제로서의 알킬티오 피리미딘
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
ES2744541T3 (es) 2008-12-08 2020-02-25 Gilead Connecticut Inc Inhibidores de imidazopirazina Syk
DK2716157T3 (en) 2008-12-08 2016-08-15 Gilead Connecticut Inc Imidazopyrazin-Syk inhibitors
WO2010147898A2 (en) * 2009-06-15 2010-12-23 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
MX2012007402A (es) 2009-12-23 2012-08-23 Takeda Pharmaceutical Pirrolidinonas heteroaromaticas fusionadas como inhibidores de tirosina cinasa esplenica (syk).
JP5938352B2 (ja) 2010-03-11 2016-06-22 ギリアード コネチカット, インコーポレイテッド イミダゾピリジンsyk阻害剤
JP2013523884A (ja) * 2010-04-14 2013-06-17 アレイ バイオファーマ、インコーポレイテッド JAKキナーゼの阻害剤としての5,7置換イミダゾ[1,2−c]ピリミジン
JP2014513687A (ja) 2011-05-10 2014-06-05 メルク・シャープ・アンド・ドーム・コーポレーション Syk阻害薬としてのピリジルアミノピリジン
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
JP2014513686A (ja) 2011-05-10 2014-06-05 メルク・シャープ・アンド・ドーム・コーポレーション Syk阻害薬としてのアミノピリミジン
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US9006444B2 (en) 2011-10-05 2015-04-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
CA2851623A1 (en) * 2011-10-12 2013-04-18 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
MX362940B (es) * 2011-12-28 2019-02-27 Fujifilm Corp Nuevo derivado de nicotinamida o la sal del mismo.
WO2013192125A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
WO2013192128A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
US9416111B2 (en) 2012-06-22 2016-08-16 Merck Sharp & Dohme Corp. Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors
WO2013192098A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2884982B1 (en) 2012-08-20 2017-09-20 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9586931B2 (en) 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
EP2931281B1 (en) 2012-12-12 2018-01-17 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase inhibitors
US9598405B2 (en) 2012-12-21 2017-03-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
WO2014176216A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
WO2014176210A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
JP6153667B2 (ja) 2013-07-30 2017-06-28 ギリアード コネチカット, インコーポレイテッド Sky阻害剤の製剤
MD4659B1 (ru) 2013-07-30 2019-11-30 Gilead Connecticut Inc Полиморф ингибиторов SYK
CN105764516A (zh) 2013-12-04 2016-07-13 吉利德科学公司 治疗癌症的方法
EP3083560B1 (en) 2013-12-20 2021-10-27 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3083559B1 (en) 2013-12-20 2021-03-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
US9775839B2 (en) 2014-03-13 2017-10-03 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
LT3119772T (lt) 2014-03-19 2019-08-26 Boehringer Ingelheim International Gmbh Heteroarilo sik inhibitoriai
MA40075A (fr) 2014-07-14 2016-01-21 Gilead Sciences Inc Combinaisons pour traiter des cancers
EP3347353B1 (en) 2015-09-11 2019-07-17 Boehringer Ingelheim International GmbH Pyrazolyl-substituted heteroaryls and their use as medicaments
US11384082B2 (en) 2017-08-25 2022-07-12 Kronos Bio, Inc. Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors
CA3079292A1 (en) 2017-10-19 2019-04-25 Bayer Animal Health Gmbh Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
CN111587114A (zh) 2017-11-14 2020-08-25 儿童医学中心公司 用于调节人免疫应答的咪唑并嘧啶的用途
US11673891B2 (en) 2017-11-14 2023-06-13 Dana-Farber Cancer Institute, Inc. Imidazopyrimidine compounds and uses thereof
WO2019235572A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 固形がんの処置剤および医薬組成物
WO2019235571A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 血液がんの処置剤および医薬組成物
JP7370079B2 (ja) * 2018-06-06 2023-10-27 国立大学法人北海道大学 グリオーマの処置剤および医薬組成物
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
IL282535B2 (en) 2018-10-31 2024-05-01 Gilead Sciences Inc Transformed 6-azabanzimidazole compounds as HPK1 inhibitors
US11339168B2 (en) 2019-02-22 2022-05-24 Kronos Bio, Inc. Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたDbait分子
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483987A (en) * 1983-06-20 1984-11-20 G. D. Searle & Co. 8-Substituted 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines and amides
CA2303830A1 (en) * 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
JP4135318B2 (ja) * 1997-12-15 2008-08-20 アステラス製薬株式会社 新規なピリミジン−5−カルボキサミド誘導体
US6673564B2 (en) * 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Also Published As

Publication number Publication date
US6911443B2 (en) 2005-06-28
EP1278750A1 (en) 2003-01-29
DE60104671D1 (de) 2004-09-09
EP1278750B1 (en) 2004-08-04
PL358106A1 (en) 2004-08-09
CA2407531A1 (en) 2001-10-25
KR20030009456A (ko) 2003-01-29
PT1278750E (pt) 2004-11-30
TR200402300T4 (tr) 2004-12-21
SV2001000416A (es) 2001-07-03
HRP20020943A2 (en) 2005-02-28
PE20011287A1 (es) 2002-02-27
MA25746A1 (fr) 2003-04-01
JP2003535067A (ja) 2003-11-25
NZ526221A (en) 2005-01-28
DOP2001000151A (es) 2002-05-15
MXPA02010579A (es) 2003-05-14
NZ522241A (en) 2004-04-30
BG107166A (bg) 2003-06-30
ZA200207676B (en) 2003-09-25
DE60104671T2 (de) 2005-12-29
TWI222974B (en) 2004-11-01
NO20025154D0 (no) 2002-10-25
EE200200606A (et) 2004-04-15
JP2001302667A (ja) 2001-10-31
ATE272639T1 (de) 2004-08-15
IL151919A0 (en) 2003-04-10
AU6220401A (en) 2001-11-12
NO20025154L (no) 2002-10-25
AR033367A1 (es) 2003-12-17
SI1278750T1 (en) 2005-02-28
US20040054179A1 (en) 2004-03-18
WO2001083485A1 (en) 2001-11-08
CN1439009A (zh) 2003-08-27
ES2225546T3 (es) 2005-03-16
SK15332002A3 (sk) 2003-06-03
CZ20023551A3 (cs) 2003-01-15
HK1058362A1 (en) 2004-05-14
RU2306313C2 (ru) 2007-09-20
BR0110404A (pt) 2003-02-11
MY141578A (en) 2010-05-14
HUP0300846A2 (hu) 2003-08-28
AU783043B2 (en) 2005-09-22
DK1278750T3 (da) 2004-11-22
CN1263756C (zh) 2006-07-12

Similar Documents

Publication Publication Date Title
UA72615C2 (en) Imidazopyrimidine and triazolopyrimidine derivatives, a method for the preparation thereof, medicament based thereon
ES2772133T3 (es) Compuestos heteroarilo como inhibidores de IRAK y sus usos
CN105026397B (zh) 作为抗癌剂的9‑(芳基或杂芳基)‑2‑(吡唑基、吡咯烷基或环戊基)氨基嘌呤衍生物
JP2021512167A (ja) 障害を治療するための方法及び化合物
ES2841452T3 (es) Macrociclos de piridazinona como inhibidores de IRAK y sus usos
CN102803216B (zh) 杂环抗病毒化合物
UA103912C2 (ru) Антитела против ангиопоэтина-2 человека
UA123785C2 (uk) Сполуки піролотриазину як інгібітори tam
UA126390C2 (uk) Циклічна динуклеотидна сполука як агоніст sting (стимулятор генів інтерферону)
UA120039C2 (uk) Селективно заміщені сполуки хіноліну
CN107001331A (zh) 作为bub1抑制剂的苄基取代的吲唑
UA77303C2 (en) Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CN109071529A (zh) 作为jak激酶抑制剂的嘧啶化合物
TW200815482A (en) Macrocyclic oximyl hepatitis C protease inhibitors
UA76977C2 (en) Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
US20210284988A1 (en) Reprogramming urokinase into an antibody-recruiting anticancer agent
ES2654403T3 (es) Derivados de imidazopirazinona
CN107531697A (zh) 3‑(1h‑苯并咪唑‑2‑基)‑1h‑吡啶‑2‑酮衍生物
US11760761B2 (en) Methods and compositions for targeting PD-L1
UA76887C2 (ru) Соединение пиперидина
UA76969C2 (en) Lactams and their pharmaceutical use
US9493461B2 (en) Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C
HUE024161T2 (hu) Kinazolindion-származékok terápiás alkalmazása kardiovaszkuláris területen
WO2001034154A1 (en) Protease inhibitors
WO2001034156A1 (en) Protease inhibitors